Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of navitoclax plus ruxolitinib versus ruxolitinib in myelofibrosis
2020-000097-15Phase 3Unknown
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Navitoclax + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Spleen volume response. Status: unknown.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-000097-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000097-15.